Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2020; 16(2):194-203. doi:10.7150/ijbs.39024 This issue Cite

Research Paper

Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice

Yu Bai1,2, Wei Wang1, Ping Yin1, Jian Gao3, Lei Na1, Yu Sun1, Zhuo Wang1, Zhongbo Zhang1, Chenghai Zhao1✉

1. Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China.
2. Department of Nephrology, Shengjing Hospital, China Medical University, Shenyang, China.
3. Center of Laboratory Technology and Experimental Medicine, China Medical University, Shenyang, China.
✉ Corresponding author: Chenghai Zhao (E-mail: chzhao@cmu.edu.cn), Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, China. Tel 86+24+31939318.

Citation:
Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int J Biol Sci 2020; 16(2):194-203. doi:10.7150/ijbs.39024. https://www.ijbs.com/v16p0194.htm
Other styles

File import instruction

Abstract

Graphic abstract

Ruxolitinib is a selective inhibitor of Jak1/2. Downstream signaling pathways of Jak, such as Stat3 and Akt/mTOR, are overactivated and contribute to renal interstitial fibrosis. Therefore, we explored the effect of Ruxolitinib on this pathological process. Unilateral ureteral obstruction (UUO) models and TGF-β1-treated fibroblasts and renal tubular epithelial cells were adopted in this study. Ruxolitinib was administered to UUO mice and TGF-β1-treated cells. Kidneys from UUO mice with Ruxolitinib treatment displayed less tubular injuries compared with those without Ruxolitinib treatment. Ruxolitinib treatment suppressed fibroblast activation and extracellular matrix (ECM) production in UUO kidneys and TGF-β1-treated fibroblasts. Ruxolitinib treatment also blocked epithelial-mesenchymal transition (EMT) in UUO kidneys and TGF-β 1-treated renal tubular epithelial cells. Moreover, Ruxolitinib treatment alleviated UUO-induced inflammation, oxidative stress and apoptosis. Mechanistically, Ruxolitinib treatment attenuated activation of both Stat3 and Akt/mTOR/Yap pathways. In conclusion, Ruxolitinib treatment can ameliorate UUO-induced renal interstitial fibrosis, suggesting that Ruxolitinib may be potentially used to treat fibrotic kidney disease.

Keywords: Ruxolitinib, Jak, Stat3, mTOR, TGF-β1

Citation styles

APA
Bai, Y., Wang, W., Yin, P., Gao, J., Na, L., Sun, Y., Wang, Z., Zhang, Z., Zhao, C. (2020). Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. International Journal of Biological Sciences, 16(2), 194-203. https://doi.org/10.7150/ijbs.39024.

ACS
Bai, Y.; Wang, W.; Yin, P.; Gao, J.; Na, L.; Sun, Y.; Wang, Z.; Zhang, Z.; Zhao, C. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int. J. Biol. Sci. 2020, 16 (2), 194-203. DOI: 10.7150/ijbs.39024.

NLM
Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int J Biol Sci 2020; 16(2):194-203. doi:10.7150/ijbs.39024. https://www.ijbs.com/v16p0194.htm

CSE
Bai Y, Wang W, Yin P, Gao J, Na L, Sun Y, Wang Z, Zhang Z, Zhao C. 2020. Ruxolitinib Alleviates Renal Interstitial Fibrosis in UUO Mice. Int J Biol Sci. 16(2):194-203.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use